Skip to search formSkip to main contentSkip to account menu

Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.

View on PubMed (opens in a new tab)

Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. colil-asparaginase preparation (MC0609) in Beagle dog

The new pegylated recombinant l-asparaginase preparation MC0609 revealed striking differences in PK/PD properties compared with Oncaspar® in rat and dog.
View on Springer (opens in a new tab)

Challenges in the analytical characterization of PEGylated asparaginase

View via Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)